These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3798415)

  • 1. Bioavailability and antagonization of the low molecular weight heparin CY 216 in man.
    Harenberg J; Würzner B; Zimmermann R; Schettler G
    Thromb Res; 1986 Nov; 44(4):549-54. PubMed ID: 3798415
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo attempt to consume antithrombin III by i.v. injection of a thrombin-heparin mixture.
    Soulier JP; Gozin D; Lerable J
    Thromb Res; 1984 May; 34(3):255-62. PubMed ID: 6729779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic use of antithrombin III for protection of haemostatic balance in patients undergoing cardiopulmonary bypass.
    Fagiano G; Parodi F; Brignolo C; Cordero G; Fabris E; Pagani L
    J Cardiothorac Anesth; 1989 Oct; 3(5 Suppl 1):87. PubMed ID: 2521020
    [No Abstract]   [Full Text] [Related]  

  • 4. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro and ex-vivo neutralizing effect of protamine sulphate on the anticoagulant activity of a new low molecular mass heparin.
    Falkon L; Garí M; Gich I; Fontcuberta J
    Thromb Res; 1998 Jan; 89(2):79-83. PubMed ID: 9630311
    [No Abstract]   [Full Text] [Related]  

  • 6. [Protamine complexes with antithrombin III and heparin].
    Roszkowska W; Worowski K
    Acta Haematol Pol; 1982; 13(1-2):25-8. PubMed ID: 7180353
    [No Abstract]   [Full Text] [Related]  

  • 7. Activation of the clotting system: heparin-coated versus non coated systems for extracorporeal circulation.
    Urlesberger B; Zobel G; Rödl S; Dacar D; Friehs I; Leschnik B; Muntean W
    Int J Artif Organs; 1997 Dec; 20(12):708-12. PubMed ID: 9506788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of protamine on heparin-antithrombin III complexes. In vitro studies.
    Kitani T; Nagarajan SC; Shanberge JN
    Thromb Res; 1980 Feb 1-15; 17(3-4):367-74. PubMed ID: 7368168
    [No Abstract]   [Full Text] [Related]  

  • 9. [In vitro and in vivo neutralisation of a low molecular weight heparin fraction CY 216 by protamine].
    Doutremepuich C; Bonini F; Masse A; Bousquet F; Bayrou B; Toulemonde F
    Ann Pharm Fr; 1986; 44(1):65-72. PubMed ID: 3777780
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mechanisms of heparin resistance and their clinical significance].
    Barkagan ZS; Lychev VG; Bishevskiĭ KM; Tsyvkina LP; Glazunova GA
    Ter Arkh; 1982; 54(8):77-82. PubMed ID: 6753220
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog.
    Hellebrekers LJ; Slappendel RJ; van den Brom WE
    Am J Vet Res; 1985 Jul; 46(7):1460-2. PubMed ID: 4026027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro comparative study of the anticoagulant action of lung and gut heparin: part 1.
    Fukuda T; Tatsumi Y; Kimura Y; Maeda H; Okuda K
    Osaka City Med J; 1980; 26(1):19-37. PubMed ID: 7267090
    [No Abstract]   [Full Text] [Related]  

  • 13. Activity of antithrombin III and effect of heparin on coagulation in shock.
    Blauhut B; Necek S; Kramar H; Vinazzer H; Bergmann H
    Thromb Res; 1980 Sep; 19(6):775-82. PubMed ID: 7466746
    [No Abstract]   [Full Text] [Related]  

  • 14. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity.
    Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation parameters and heparin levels in open-heart surgery.
    Cullmann W; Müller N; Lie TB; Kladetzky RG; Jürgens P
    Res Exp Med (Berl); 1980; 177(2):111-7. PubMed ID: 7444168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bypass surgery on coagulation-sensitive clotting factors.
    Woods JE; Kirklin JW; Owen CA; Thompson JH; Taswell HF
    Mayo Clin Proc; 1967 Nov; 42(11):724-35. PubMed ID: 6053800
    [No Abstract]   [Full Text] [Related]  

  • 17. [The inhibitory effects of histidine-rich glycoprotein on the anticoagulant activity of heparin].
    Niwa M
    Nihon Ketsueki Gakkai Zasshi; 1988 Nov; 51(7):1130-7. PubMed ID: 3223216
    [No Abstract]   [Full Text] [Related]  

  • 18. Synergistic effect of antithrombin III, activated protein C and heparin on the inhibition of the tissue thromboplastin-mediated coagulation.
    Hirahara K; Etoh Y; Matsuishi T; Suzuki N; Kurata M
    Chem Pharm Bull (Tokyo); 1989 Mar; 37(3):692-6. PubMed ID: 2752479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No effect of cloricromen on some coagulation parameters in patients with ischaemic cerebrovascular disease.
    Orefice G; Grasso A; Fazio N; Del Vecchio G; Volpe G; Coppola M; D'Alessio A; Carrieri PB
    J Int Med Res; 1994; 22(5):287-91. PubMed ID: 7867874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin) in man by protamine chloride.
    Andrassy K; Eschenfelder V; Weber E
    Thromb Res; 1994 Jan; 73(2):85-93. PubMed ID: 8171416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.